MDM2, a negative regulator of the p53 tumor suppressor, played key roles in mediating the anti-tumor effects of SIRT6, as it degraded SIRT6 via the proteasome-dependent pathway, then effectively decreased the proportion of HNSCC cells in the G1 phase, indicative of cell death [110]. Here, SIRT6 is linked to neoplasm.